Ahmad Tarhini, MD, PHD
Moffitt Cancer Center · University of Pittsburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ahmad Tarhini, MD, PHD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06295159 · Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma · principal investigator
- Ph2NCT06121180 · Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Metastatic Uveal Melanoma · principal investigator
- Ph2NCT05170334 · Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Metastatic Uveal Melanoma · principal investigator
- Ph1NCT04975152 · Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma · principal investigator
- Ph2NCT04562129 · IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Melanoma Stage III, Melanoma Stage IV, Inoperable Disease · principal investigator
- Ph2NCT04526730 · Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma · principal investigator
- Ph1/Ph2NCT02736123 · Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneUniversity of Pittsburgh · withdrawn · Melanoma · principal investigator
- Ph2NCT00374140 · Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung CancerAhmad Tarhini · completed · Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.